We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Are GlaxoSmithKline plc & National Grid plc The Only Shares You Need To Own?

Roland Head asks whether National Grid plc (LON:NG) and GlaxoSmithKline plc (LON:GSK) have market-beating potential.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Is it possible to run a successful portfolio with just two shares? I wouldn’t recommend it, but if I decided to try, National Grid (LSE: NG) and GlaxoSmithKline (LSE: GSK) would probably be on my shortlist of stocks to consider.

Both companies appear to offer a combination of reliable long-term growth and generous dividend yields. Both firms are also very large. Together, National Grid and Glaxo account for 5.7% of the FTSE 100’s total market capitalisation. This makes them less likely than smaller companies to fail, although long periods of underperformance are still possible.

Should you buy National Grid Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Not likely to underperform?

Indeed, many investors believe that GlaxoSmithKline has been underperforming over the last few years. Although the dividend has been maintained, the firm’s shares are currently trading 15% below their July 2013 high of 1,745p.

However, things now seem likely to change. Glaxo completed a major asset swap deal with Swiss firm Novartis last year. The firm’s sales rose by 4% and while profits were lower, a number of new products made a strong contribution for the first time.

I believe Glaxo’s restructuring has positioned it to deliver a sustained period of growth. Adjusted earnings per share are expected to rise to 85.3p this year, covering the firm’s forecast dividend of 81.9p per share for the first time in three years.

There’s also one more big change in the pipeline. The group’s chief executive, Sir Andrew Witty, is expected to leave next year. If GlaxoSmithKline shares continue to underperform the market, I suspect its next chief executive will come under pressured to break up the group.

Fund managers such as Neil Woodford hold the view that Glaxo would be worth more as two or three companies than it is as one. I suspect he’s right, although I like the defensive nature of Glaxo’s diverse portfolio.

In the meantime, I believe GlaxoSmithKline’s 5.5% dividend yield and long-term growth potential make the shares a strong buy.

Heading in the opposite direction?

While GlaxoSmithKline may have underperformed the market, National Grid hasn’t.

Over the last five years, shares in National Grid have risen by 69%, compared to just 3% for the FTSE 100. The two other large listed power utilities in the UK, SSE and Centrica, have also lagged National Grid. Centrica has fallen by nearly 30% over the same period, while SSE has gained just 17%.

National Grid also has a couple of other attractive features. The firm’s US utility business helps diversify the group’s operations and reduce its dependency on the UK market. Another attraction is that unlike electricity generators like SSE and Centrica, National Grid’s direct exposure to coal, oil and gas prices is very low.

I can’t see any reason why National Grid’s business can’t continue to perform strongly. My only reservation is that the shares are no longer obviously cheap. Dividend growth has now slowed to just 1% to 2% a year. And National Grid’s 4.3% yield is well below the 6% on offer from SSE.

However, analysts have a positive outlook for the next couple of years. Forecast earnings for 2015/16 have risen by 5.5% over the last year. There’s a real possibility that National Grid will continue to outperform its utility peers.

Roland Head owns shares of GlaxoSmithKline and SSE. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »